Systematic review evaluates intranasal insulin effects on cognitive outcomes in mild cognitive impairment and Alzheimer’s disease, indicating potential benefits.
To evaluate the efficacy and safety of Intranasal insulin therapy in improving cognitive, functional, and behavioral outcomes among individuals with mild cognitive impairment (MCI) and Alzheimer’s disease (AD).
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: